Bob Hopkins

In a report published Monday, Bank of America analyst Bob Hopkins initiated coverage on Cardiovascular Systems (NASDAQ: CSII) with a Buy rating and $38.00 price target. In the report, Bank of America noted, “We are initiating coverage on CSII, maker of a differentiated atherectomy system for...

In a report published Wednesday, Bank of America analyst Bob Hopkins reiterated a Neutral rating on Johnson & Johnson (NYSE: JNJ), and raised the price target from $95.00 to $106.00. In the report, Bank of America noted, “Based on JNJ's very strong Q1 performance, we are raising our PO for JNJ...

In a report published Monday, Bank of America analyst Bob Hopkins upgraded the rating on Boston Scientific Corporation (NYSE: BSX) from Neutral to Buy, and raised the price target from $15.00 to $16.00. In the report, Bank of America noted, “We are upgrading BSX to Buy and raising our PO to $16...

In a report published Tuesday, Bank of America analyst Bob Hopkins downgraded the rating on C.R. Bard (NYSE: BCR) from Buy to Neutral, but reiterated the $150.00 price target. In the report, Bank of America noted, “We are moving our rating on BCR to Neutral from Buy today for two reasons. First,...

In a report published Monday, Bank of America analyst Bob Hopkins reiterated a Neutral rating on Edwards Lifesciences (NYSE: EW), and raised the price target from $67.00 to 75.00. In the report, Bank of America noted, “Over the next 5+ years, there is no other new product opportunity in medtech of...

In a report published Wednesday, Bank of America analyst Bob Hopkins reiterated a Buy rating on CareFusion (NYSE: CFN), and raised the price target from $43.00 to $45.00. In the report, Bank of America noted, “Last week we attended the American Society of Health-System Pharmacists (ASHP) meeting...

In a report published Monday, Bank of America analyst Bob Hopkins initiated coverage on Tandem Diabetes Care (NASDAQ: TNDM) with a Neutral rating and $27.00 price target. In the report, Bank of America noted, “We are initiating coverage on TNDM, maker of the first truly consumer friendly durable...

In a report published Thursday, Bank of America analyst Bob Hopkins reiterated a Buy rating on C.R. Bard (NYSE: BCR), and raised the price target from $125.00 to $140.00. In the report, Bank of America noted, “We are raising our PO for BCR to $140 today after our recent meetings with BCR's CEO and...